NASDAQ:CEMI

Chembio Diagnostics - CEMI Stock Forecast, Price & News

$0.39

+0.01 (+2.63%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.38
▼
$0.40
50-Day Range: $0.33
▼
$0.45
52-Week Range: $0.19
▼
$1.24

Volume: 529,058 shs
Average Volume: 550,037 shs
Market Capitalization: $14.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Chembio Diagnostics (NASDAQ:CEMI) Stock

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

March 22, 2023 | americanbankingnews.com

Chembio Diagnostics (NASDAQ:CEMI) Now Covered by Analysts at StockNews.com

March 21, 2023 | finance.yahoo.com

Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023

March 25, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

March 15, 2023 | finance.yahoo.com

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

March 15, 2023 | finance.yahoo.com

Chembio Announces Letter to Stockholders Regarding Tender Offer

February 24, 2023 | finance.yahoo.com

Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System

February 8, 2023 | benzinga.com

Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm

February 2, 2023 | wsj.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chembio Diagnostics, Inc. Buyout

March 25, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

February 1, 2023 | finance.yahoo.com

French Rapid Testing Company Scoops Up Chembio Diagnostics For $17M

January 31, 2023 | finance.yahoo.com

Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

January 21, 2023 | seekingalpha.com

CEMI Chembio Diagnostics, Inc.

January 7, 2023 | forbes.com

Chembio Diagnostics

November 28, 2022 | finance.yahoo.com

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

November 6, 2022 | seekingalpha.com

Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call Transcript

November 3, 2022 | finance.yahoo.com

Chembio Diagnostics Reports Third Quarter 2022 Financial Results

October 20, 2022 | finance.yahoo.com

Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022

September 6, 2022 | finance.yahoo.com

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

September 3, 2022 | finance.yahoo.com

Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed

August 16, 2022 | finance.yahoo.com

Rapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It Off

August 16, 2022 | finance.yahoo.com

Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development

August 4, 2022 | finance.yahoo.com

Chembio Diagnostics Reports Second Quarter 2022 Financial Results

July 21, 2022 | finance.yahoo.com

Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022

June 15, 2022 | baystreet.ca

Chembio Expands Distribution

June 15, 2022 | finance.yahoo.com

Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel

May 17, 2022 | seekingalpha.com

Chembio's inks contract for HIV test to be made by Reszon Diagnostics at Malaysia facility

May 17, 2022 | finance.yahoo.com

Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Company Calendar

Last Earnings: 11/04/2021
Today: 3/25/2023
Next Earnings (Estimated): 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CEMI
CUSIP: N/A
CIK: 1092662
Web: www.chembio.com
Phone: (631) 924-1135
Fax: 631-924-2065
Employees: 337
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,900,000.00
Net Margins: -60.93%
Pretax Margin: -60.91%
Return on Equity: -129.14%
Return on Assets: -50.01%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 1.22
Quick Ratio: 1.00

Sales & Book Value

Annual Sales: $47.82 million
Price / Sales: 0.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.14 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 36,710,000
Free Float: 35,497,000
Market Cap: $14.32 million
Optionable: Not Optionable
Beta: 1.83

Key Executives

Richard L. Eberly
President, Chief Executive Officer & Director

Paul J. Angelico
Chief Operations Officer & Executive VP

Lawrence J. Steenvoorden
Chief Financial Officer, Secretary & Executive VP

Javan Esfandiari
Executive VP, Chief Science & Technology Officer

Paul Lambotte
Vice President-Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CEMI Stock - Frequently Asked Questions

How have CEMI shares performed in 2023?: Chembio Diagnostics' stock was trading at $0.2197 at the start of the year. Since then, CEMI shares have increased by 77.5% and is now trading at $0.39.
View the best growth stocks for 2023 here.
When is Chembio Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CEMI earnings forecast.
How were Chembio Diagnostics' earnings last quarter?: Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The company had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative net margin of 60.93% and a negative trailing twelve-month return on equity of 129.14%. During the same period in the prior year, the company earned ($0.28) earnings per share.
What other stocks do shareholders of Chembio Diagnostics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK).
What is Chembio Diagnostics' stock symbol?: Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?: Chembio Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Chembio Diagnostics?: Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Chembio Diagnostics' stock price today?: One share of CEMI stock can currently be purchased for approximately $0.39.
How much money does Chembio Diagnostics make?: Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $14.32 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.
How many employees does Chembio Diagnostics have?: The company employs 337 workers across the globe.
How can I contact Chembio Diagnostics?: Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065.

This page (NASDAQ:CEMI) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chembio Diagnostics - CEMI Stock Forecast, Price & News

About Chembio Diagnostics (NASDAQ:CEMI) Stock

CEMI Stock News Headlines

CEMI Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CEMI Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info